Royal Bank of Canada Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $148.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $154.00 to $148.00 in a report released on Friday,Benzinga reports. The brokerage currently has a sector perform rating on the stock. A number of other research firms have also recently weighed in on NBIX. Canaccord Genuity Group lowered […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $154.00 to $148.00 in a report released on Friday,Benzinga reports. The brokerage currently has a sector perform rating on the stock. A number of other research firms have also recently weighed in on NBIX. Canaccord Genuity Group lowered […]
